Sarepta Therapeutics, Inc. SRPT Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Liquidity | ||||||
| Current ratio | 4.6×+0.6× | 2.3×-1.9× | 3×-0.9× | 2.9×-1.0× | 4×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.2×0.0× | 0.2×-0.1× | 0.2×-0.1× | 0.2×-0.1× | |
| Valuation | ||||||
| Market capitalization | $2.28B-63.1% | $2.26B-80.6% | $2.02B-82.9% | $1.87B-87.4% | $6.19B-49.1% | |
| Price / book | 1.5×-3.9× | 2×-5.6× | 1.5×-8.1× | 1.4×-12.4× | 5.4×-7.2× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Sarepta Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Sarepta Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
